Transcatheter Aortic Valve Implantation for Pseudoaneurysm of the Mitral‐Aortic Intervalvular Fibrosa Causing Severe Aortic Regurgitation
Catheterization and Cardiovascular Interventions · 2026-08 · 108 (2) · 446-451
DOI: 10.1002/ccd.70673 ↗Kurz gefasst
Fallbericht in der Zeitschrift Catheterization and Cardiovascular Interventions, online erschienen am 27.05.2026. Verfasst von Paula Vela Martín und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Interventional Cardiology, University Hospital Arnau de Vilanova Lleida, Lleida, Spain. Hauptthemen laut MEDLINE: Aortic Valve Insufficiency, Aneurysm, False, Aortic Valve, Heart Aneurysm. Die Arbeit nennt 14 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Biomedical Research Foundation of University Hospital Puerta de Hierro Majadahonda.
Abstract (Originalsprache)
Pseudoaneurysm of the mitral‐aortic intervalvular fibrosa (P‐MAIVF) is a rare complication following infective endocarditis or valve surgery. We report the case of a 65‐year‐old male who developed a P‐MAIVF following surgical mitral valve replacement for infective endocarditis. Shortly after the surgery, although the patient remained afebrile and blood cultures were negative, routine transthoracic echocardiography revealed new‐onset severe aortic regurgitation. Multimodality imaging confirmed a P‐MAIVF extending into the non‐coronary sinus and the left ventricular outflow tract, causing valvular incompetence despite a structurally normal aortic valve. Given the prohibitive surgical risk, an off‐label transcatheter aortic valve implantation (TAVI) using a 34 mm self‐expanding Evolut FX prosthesis was performed, aiming to exclude the pseudoaneurysm. Despite technical challenges related to the absence of annular calcification and catheter misplacement into the pseudoaneurysm, the prosthesis was successfully implanted with full exclusion of the pseudoaneurysm. At 3‐month follow‐up, the patient remained asymptomatic, with no residual aortic regurgitation and complete exclusion of the P‐MAIVF on CTA. To our knowledge, this is the first reported case of a native, non‐calcified aortic root pseudoaneurysm causing severe aortic regurgitation successfully treated with off‐label TAVI. Multimodal imaging and careful preprocedural planning were key to procedural success.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Interventional Cardiology, University Hospital Arnau de Vilanova Lleida, Lleida, Spain.
- Department of Interventional Cardiology, University Hospital Puerta de Hierro Majadahonda, Madrid, Spain.
- Department of Cardiology, University Hospital Puerta de Hierro Majadahonda, Madrid, Spain.
Förderung
- Biomedical Research Foundation of University Hospital Puerta de Hierro Majadahonda
Zitieren
APA
Martín, P. V., Garcia-Touchard, A., Palomero, V. M., & Dominguez, J. F. O. (2026). Transcatheter Aortic Valve Implantation for Pseudoaneurysm of the Mitral‐Aortic Intervalvular Fibrosa Causing Severe Aortic Regurgitation. Catheterization and Cardiovascular Interventions, 108(2), 446-451. https://doi.org/10.1002/ccd.70673
Vancouver
Martín PV, Garcia-Touchard A, Palomero VM, Dominguez JFO. Transcatheter Aortic Valve Implantation for Pseudoaneurysm of the Mitral‐Aortic Intervalvular Fibrosa Causing Severe Aortic Regurgitation. Catheterization and Cardiovascular Interventions. 2026;108(2):446-451. doi:10.1002/ccd.70673
BibTeX
@article{Martn2026,
author = {Martín, Paula Vela and Garcia-Touchard, Arturo and Palomero, Vanessa Moñivas and Dominguez, Juan Francisco Oteo},
title = {Transcatheter Aortic Valve Implantation for Pseudoaneurysm of the Mitral‐Aortic Intervalvular Fibrosa Causing Severe Aortic Regurgitation},
journal = {Catheterization and Cardiovascular Interventions},
year = {2026},
volume = {108},
number = {2},
pages = {446--451},
doi = {10.1002/ccd.70673}
}
EUVIMED